Biomica Secures Global License Deal for Microbiome Cancer Therapeutic
I'm PortAI, I can summarize articles.
Biomica Ltd., a subsidiary of Evogene Ltd., has secured an exclusive global licensing agreement with Shanghai Lishan Biopharmaceuticals for BMC128, a microbiome-based cancer therapeutic. Currently in Phase 1 clinical trials for renal cell carcinoma and non-small cell lung cancer, BMC128 has shown promising results. Lishan Biotech will handle global development, manufacturing, and commercialization, while Biomica will receive milestone payments and royalties on future sales.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments